Key Insights

Highlights

Success Rate

81% trial completion

Published Results

18 trials with published results (11%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

6.5%

11 terminated out of 168 trials

Success Rate

81.4%

-5.2% vs benchmark

Late-Stage Pipeline

14%

24 trials in Phase 3/4

Results Transparency

38%

18 of 48 completed with results

Key Signals

18 with results81% success11 terminated

Data Visualizations

Phase Distribution

112Total
Not Applicable (36)
Early P 1 (5)
P 1 (27)
P 2 (20)
P 3 (10)
P 4 (14)

Trial Status

Recruiting62
Completed48
Not Yet Recruiting33
Terminated11
Unknown5
Active Not Recruiting5

Trial Success Rate

81.4%

Benchmark: 86.5%

Based on 48 completed trials

Clinical Trials (168)

Showing 20 of 20 trials
NCT07085676Phase 1Recruiting

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

NCT07258849Phase 1RecruitingPrimary

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

NCT03971253RecruitingPrimary

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

NCT07564154Phase 1Not Yet RecruitingPrimary

A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)

NCT06670183Active Not RecruitingPrimary

Dietary Factors and Rheumatoid Arthritis Risk in the UK Biobank

NCT06933134RecruitingPrimary

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

NCT07553871Not Yet Recruiting

Comparative Study on the Medium- and Long-term Benefits of Prosthesis Selection in Total Knee Arthroplasty

NCT07536529Recruiting

Oxidative Stress in Autoimmune Rheumatic Diseases

NCT07359326Not ApplicableCompleted

The Effect of Cold Application in Patients With Rheumatoid Arthritis

NCT07544225Phase 1Not Yet RecruitingPrimary

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

NCT07123038RecruitingPrimary

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07524244Not ApplicableRecruitingPrimary

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07087912Phase 4RecruitingPrimary

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07473154Phase 1Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07527936Early Phase 1Not Yet Recruiting

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

NCT07525856Not ApplicableNot Yet RecruitingPrimary

Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis

NCT07245732Phase 4RecruitingPrimary

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

NCT06791980Not ApplicableCompletedPrimary

Integrated Care Approach for Rheumatoid Arthritis Patients

NCT07487779Not ApplicableNot Yet RecruitingPrimary

Efficacy of Structured Progressive Training Exercise on Muscle Strength of Patients With Rheumatoid Arthritis

NCT06647069Phase 1Recruiting

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Scroll to load more

Research Network

Activity Timeline